Really the only thing that has changed is the decision to forego OTC MMJ markets where our products would be sold unlabeled. Developing a cream for psoriasis and then not being able to sell it as such defeats the purpose of its development and of the company itself. I don't know what the requirements are for the cream to be a prescription item but I believe they are far less stringent in countries outside of the US. With safety and some form of efficacy established we may be looking at several markets where the cream could be labeled and sold for it's intended purpose. Germany, Israel, and several other markets come to mind.